The article emphasizes using both clinical judgment and guidelines, balancing evidence with individualized patient care.

Since quality has many dimensions, we must worry that focusing on some dimensions will decrease our attention to other important dimensions.

I hope we can find a company (or more than one) who would develop a point-of-care test for Fusobacterium necrophorum.

We all need a roadmap for true improvement. I think MOC could provide that roadmap. If so, then MOC would be most valuable.

All attempts at measuring quality in medicine depend on correct diagnosis. Diagnostic accuracy represents the lynchpin of high quality care. As everyone knows, the first

This problem is common. The ACP Performance Measurement Committee reviews submitted measures and evaluates them in a very careful.

it is an increasingly common one. I am tired of hearing it. But do the perpetrators of this nonsense understand in any meaningful way?

Some issues deserve multiple opinions. Trying to shoehorn this complexity into a precise guideline leads to unintended consequences.

So what is the solution? We should delay labeling patients with diagnoses until we have enough information to assess a high probability.

Overall the panel deserves a strong B+. They could have received an A if they had not tried so hard to include large numbers.